United Kingdom (UK)
Recombinant monoclonal antibody to haloperidol. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma Clone D.
Alternative Name(s) of Target: Haldol; 258(2)-1; D; Einalon S; Eukystol; Aloperidin; Bioperidolo; Brotopon; Dozic; Duraperidol; Halosten; Keselan; Linton; Peluces; Serenace; Sigaperidol
Immunogen: This antibody was raised by immunising mice with a haloperidol coupled to BSA via an aminooxyacetic acid arm through the keto group of
the butyrophenone chain (oxime conjugate).
Specificity: Thi antibody recognises haloperidol which is one of the major antipsychotic drugs. It is a D2 dopamine receptor antagonist and is widely used in treatment of schizophrenia, psychoses and mania. This antibody binds to the p-chlorophenyl ring (ring 2) of haloperidol and prefers an extended conformer of the drug molecule.
Application Notes: RIA: radioligand binding assays were performed to asses binding affinity of the anti-haloperidol D antibody (Kd=4.4 nM). This antibody possesses a binding site which is highly sensitive to the electron-withdrawing characteristics of the substituents on ring 2 (Sherman et al., 1986).
Antibody first published in:
Bolger et al. Preparation and characterization of antisera and monoclonal antibodies to haloperidol. Immunol Invest. 1985 Dec;14(6):523-40. PMID:2420719
Note on publication:
This article describes the preparation of the monoclonal antibodies which specifically bind haloperidol, among them this 258(2)-i antibody (later renamed as anti-haloperidol antibody D).